OS and PFS probabilities after CD19 CAR T-cell immunotherapy with concurrent ibrutinib. OS and PFS probabilities in CLL patients according to response by the 2018 iwCLL criteria (A-B) and marrow response by IGH sequencing (sensitivity 10⁻⁶) (C-D). Data are from patients evaluable for response (n = 18). (C-D) Data from patients who achieved MRD-negative marrow response by flow cytometry (n = 13), categorized according to the presence (n = 2) or absence (n = 11) of the residual malignant clone in the marrow by IGH sequencing. The solid lines represent the Kaplan-Meier estimates; the dashed lines represent 95% CIs. The P values were calculated using the log-rank test.